Abstract. Incomplete recovery of myocardial contraction after reperfusion following brief ischemia is called the "stunning phenomenon" in an animal experiment. A hydrophilic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) does not affect this phenomenon, but lipophilic statins further reduce the contraction during reperfusion. The effects of novel hydrophilic rosuvastatin and lipophilic pitavastatin on myocardial stunning in dogs were examined. In a preliminary experiment in vitro, pitavastatin reduced L6 cell viability at 10 −6 M and higher, whereas rosuvastatin and pravastatin up to 10 −5 M did not show such effects. An empty capsule or a capsule filled with rosuvastatin (2 mg / kg per day) or pitavastatin (0.4 mg / kg per day) was orally administered to dogs. After 3 weeks, both statins lowered the serum cholesterol level to the same extent. Under pentobarbital anesthesia, dogs were subjected to 15-min ischemia followed by 120-min reperfusion. Ischemia arrested the myocardial contraction in the ischemic area, and reperfusion recovered it but incompletely, showing the stunning phenomenon. Rosuvastatin did not modify the stunning phenomenon, while pitavastatin further deteriorated the myocardial contraction during reperfusion.
Introduction
3-Hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors (statins) are effective at lowering blood cholesterol level and are given to patients with hypercholesterolemia or hyperlipidemia. Reduction of serum cholesterol reduces risk of cardiovascular disease. However, in some earlier clinical trials, statins did not always show a significant reduction of cardiac events, although the studies clearly showed the cholesterol lowering and angiographic regression of atherosclerosis (1) . Pretreatment of dogs with simvastatin, but not pravastatin, decreases the myocardial level of coenzyme Q 10 and ATP generation in mitochondria (2) and deteriorates myocardial stunning (3) . Myocardial stunning is based on experimental findings, defined as a reversible contractile dysfunction during reperfusion after brief ischemia, and it happens in absence of necrosis (4) . Besides biosynthesis of cholesterol, mevalonic acid is the precursor of isoprenoids that are constituents in many substances, such as ubiquinone, dolichol, heme A, isopentenyl adenine, and farnesyl and geranylgeranyl proteins, in many organs (5) . Since ubiquinones play an important role in the mitochondrial respiratory chain, inhibition of HMG-CoA reductase may influence myocardial energy generation, particularly under pathological conditions. Lipophilic statins can enter the myocardial cell and inhibit the myocardial HMG-CoA reductase (6) . We have confirmed that several lipophilic statins (atorvastatin, fluvastatin, and cerivastatin) enhance the myocardial stunning in association with ATP reduction (7) , while the hydrophilic statin did not do that.
Partition coefficients (n-octanol / phosphate buffer) of the newly developed statins rosuvastatin and pitavastatin are logD −0.33 and logD 1.49, respectively, suggesting that the former is hydrophilic and the latter is lipophilic (8, 9) . Rosuvastatin is less hydrophilic than pravastatin having a logD −0.84. Both are now used for patients with hypercholesterolemia or hyperlipidemia. The present study was undertaken to examine whether hydrophilic rosuvastatin would behave similarly to pravastatin in an anesthetized dog myocardium (3, 7) . In the in vitro experiment, we examined the effects of these statins on L6 cell viability in order to confirm whether the statins can penetrate the cell membrane or not.
Materials and Methods
The animal experimental plan used here has been approved by the Committee of laboratory Animal Center and conforms to the Guide for the care and use of laboratory animals published by the Hokkaido Pharmaceutical University School of Pharmacy (published, 1988; revised, 2001 and 2007) .
L6 myoblast cell viability in vitro
Cell line L6 derived from rat skeletal muscle was purchased from Health Science Research Resources Bank (Osaka). L6 myoblast cells (5 × 10
3
) were seeded into a 96-well plate and preincubated in medium containing 10% fetal calf serum at 37°C with a 5% CO 2 in an incubator for 24 h and then incubated in medium containing 1% fetal calf serum and rosuvastatin, pitavastatin, or pravastatin at the indicated concentrations for 48 h. Cell viability was assessed by activity of mitochondrial dehydrogenase using the tetrazolium compound WST-8. WST-8 was added to the above cells and incubated for a further 2 h. The activities were determined by absorbance at 450 nm using microtiter-plate reader.
Protocol of animal experiments in vivo
Twenty-six healthy beagle dogs of either sex weighing 9.0 ± 0.1 kg were used and orally administered a gelatin capsule filled with either rosuvastatin (2 mg / kg per day) to 10 dogs or pitavastatin (0.4 mg / kg per day) to 9 dogs once a day at 6 P.M. for 3 weeks. An empty capsule was given to 7 dogs as the vehicle-treated group. After 3 weeks of treatment, all animals were anesthetized with pentobarbital (30 mg / kg, i.v.) and then surgery was performed on them as described in our previous paper (3, 7) . Briefly, the main trunk of the left anterior descending coronary artery (LAD) was dissected free and ligated for 15 min and then released for 120 min, that is, 15-min ischemia and 120-min reperfusion. The LAD flow was determined by an ultrasound flow meter. A flow probe was positioned distal to the first diagonal branch. Myocardial contractile function was assessed as segment shortening measured by a pair of ultrasonic crystals implanted in a circumferential plane at the LAD region that would be ischemic. The value of segment shortening was calculated as [(diastolic segment length − systolic segment length) / diastolic segment length] (7). Left ventricular pressure and its first derivative (LVdP/ dT) were measured through a cannula inserted into the left ventricular cavity from the apex. Arterial blood pressure and heart rate were also monitored.
Assay of tissue metabolites
After the experiment was completed, a transmural full thickness sample of the myocardium was removed from the LAD region. The samples were immediately pressed and frozen with clamps previously chilled in liquid N 2 . The subendocardial portion of the frozen sample was pulverized in a mortar with a pestle precooled in liquid N 2 (10). The fine frozen tissue powder was extracted with 6% perchloric acid. The levels of ATP, ADP, AMP, creatine phosphate, glucose-6-phosphate, fructose-6-phosphate, fructose-1,6-diphosphate, pyruvate, and lactate were determined in neutralized perchloric acid extracts according to standard enzymatic procedures.
Assay of serum cholesterol level
The venous blood sample was taken before and 3 weeks after statin treatment. The level of serum total cholesterol was determined by an assay kit, Cholesterol E-test Wako
Statistical analyses
All data are expressed as means ± S.E.M. of 7 -9 independent experiments. Hemodynamic data were analyzed using ANOVA with repeated measurements for overall effect of the treatments followed by Dunnett's post-hoc procedures. The significance of differences in the metabolites between groups was evaluated using an unpaired Student's t-test. The significance of differences in the hemodynamics within a group was evaluated using a paired Student's t-test. P<0.05 was considered statistically significant. Figure 1 shows the cell viability of L6 myoblasts in vitro. In this preliminary experiment, pravastatin was also tested as the representative hydrophilic statin. Exposure of L6 myoblasts to rosuvastatin and pravastatin at the concentration of 10 −7 -10 −5 M did not show any effect on the cell viability. On the other hand, pitavastatin diminished cell viability in a dose-dependent manner.
Results

L6 myoblast cell viability
Mortality and exclusion
Initially, 26 dogs were included in the in vivo experiment. However, one dog in the rosuvastatin group and one dog in the pitavastatin group died because of reperfusion arrhythmia, and were excluded from the data analysis. Therefore, the vehicle group consisted of 7 dogs, the rosuvastatin group consisted of 9 dogs, and the pitavastatin group consisted of 8 dogs.
Serum cholesterol level
Both statins lowered significantly serum cholesterol levels while vehicle did not (Fig. 2) .
Myocardial contractile function
The values of segment shortening before the onset of ischemia were 0.22 ± 0.02 in the vehicle group, 0.24 ± 0.03 in the rosuvastatin group, and 0.23 ± 0.01 in the pitavastatin group. There was no significant difference in the values among groups. The values of segment shortening were normalized to the respective preischemic values and are shown in Fig. 3 as myocardial contractile function. In all groups, myocardial contraction decreased significantly during ischemia. The decreased contractile function returned toward preischemic levels after reperfusion, but recovery of myocardial contraction was incomplete. Changes in the . Serum cholesterol levels before and 3 weeks after administration of rosuvastatin and pitavastatin. Either an empty gelatin capsule (vehicle; circle, n = 7) or a capsule filled with rosuvastatin (2 mg/kg per day; square, n = 9) or pitavastatin (0.4 mg /kg per day; triangle, n = 8) was orally given once a day to dogs for 3 weeks. Values are means ± S.E.M., n = 7 -9 in each group. *P<0.05, compared with the value obtained before administration. Fig. 3 . Myocardial contractile function of the ischemic/ reperfused area. Dogs were given an empty capsule (vehicle; circle, n = 7), rosuvastatin (2 mg / kg per day, p.o.; square, n = 9), or pitavastatin (0.4 mg/ kg per day, p.o.; triangle, n = 8) once a day for 3 weeks. After 3 weeks of administration, animals were subjected to surgery in which the left anterior descending coronary artery (LAD) was ligated for 15 min (ischemia) and then released for 120 min (reperfusion). Myocardial contractile function was assessed as segment shortening measured by a pair of ultrasonic crystals implanted in the region that would be ischemic when the LAD was ligated. The values of segment shortening were normalized to the corresponding preischemic values (at 0 min). Data are expressed as means ± S.E.M., n = 7 -9 in each group. *P<0.05, compared with the effect of treatment on recovery of myocardial contraction during reperfusion. Symbols indicating significance within group are not shown to avoid complexity.
contractile function during reperfusion in the rosuvastatin group were not significantly different from those in the vehicle group. However, the recovery of contractile function during reperfusion was significantly attenuated in the pitavastatin group compared to that in the vehicle group.
Hemodynamic changes
Hemodynamic data are summarized in Table 1 . These values were obtained after continuous 3-week administration of statins. There were some variations in heart rate and LVdP/ dT among groups. After the onset of ischemia, the LAD flow became 0 ml / min, and the left ventricular end diastolic pressure (LVEDP) increased significantly in all groups. Reperfusion caused more than 3-fold increase in the LAD flow within a minute but transient (reactive hyperemia) in all groups (data not shown). There was no significant difference in this parameter between the groups. The restoration of LVEDP in the pitavastatin group appeared to be delayed as compared to that in the vehicle group, although the difference was not statistically significant.
Myocardial metabolite levels
Myocardial tissue levels of energy and glycolytic metabolites in 120-min-reperfused hearts are summarized in Table 2 . The levels of ATP and ADP in the pitavastatin group were significantly lower than those in the vehicle group (Table 2) . However, there was no significant difference in the levels of energy metabolites Dogs were orally given an empty capsule (vehicle, n = 7), rosuvastatin (2 mg/kg per day, n = 9), or pitavastatin (0.4 mg/kg per day, n = 8) once a day for 3 weeks. After 3 weeks of administration, surgery was performed on the animals and the left anterior descending coronary artery (LAD) was ligated for 15 min (ischemia) and then released for 120 min (reperfusion). Systolic and diastolic blood pressures, heart rate, LAD flow, left ventricular end diastolic pressure (LVEDP), and the first derivative of left ventricular pressure (LVdP /dT) were measured throughout each experiment. Data are expressed as means ± S.E.M. *P<0.05, compared to the corresponding values of "Before ischemia".
between the vehicle group and rosuvastatin group. Neither rosuvastatin nor pitavastatin affected the glycolytic metabolites in the 120-min-reperfused myocardium.
Discussion
Tissue selectivity among statins has been noted by many investigators (3, 6, 11) . Because the hepatic cell membrane contains organic anion transporters that take hydrophilic substances into the cell (12), pravastatin and rosuvastatin are very effective in inhibiting cholesterol synthesis in hepatocytes (13, 14) . As a result, rosuvastatin was able to decrease the serum level of total cholesterol to the same extent as pitavastatin (Fig. 2) . On the other hand, lipophilic substances can easily penetrate the cell membrane and enter any cell. In some cells, inhibition of the mevalonic pathway may cause a loss of essential substances for cell functions. Before we carried out the experiment in vivo using dogs, we confirmed the characteristics of the statins in vitro. Lipophilic statins induce apoptotic cell death in rat pulmonary vein endothelial cells (PVEC), whereas hydrophilic pravastatin does not (15) . Because loss of viability of rat PVEC induced by lipophilic statins is abolished by addition of mevalonic acid, these statins enter the cells and inhibit the HMG-CoA reductase inside the cell. As shown in Fig. 1 , pitavastatin markedly reduced the cell viability of L6 myoblasts, whereas pravastatin and rosuvastatin did not. This finding confirms that rosuvastatin and pravastatin do not penetrate the myocardial cell membrane as described by Nezasa et al. (14) .
We clearly showed that hydrophilic rosuvastatin did not show a significant deterioration of myocardial stunning as compared to vehicle (Fig. 3) . On the other hand, lipophilic pitavastatin deteriorated the myocardial stunning similar to those of the other lipophilic statins (7). In addition, pitavastatin appeared to delay the restoration of LVEDP, which had been increased by ischemia, during reperfusion as compared to the vehicle group (Table 1) . Pitavastatin could prevent ubiquinone biosynthesis in the dog myocardium through inhibition of HMG-CoA reductase. We have demonstrated before that simvastatin decreased the myocardial level of ubiquinone in dogs (2) . A component of ubiquinone that is essential for energy production is derived from mevalonate through the respiratory chain in mitochondria. In fact, the worsening of myocardial stunning with pitavastatin was associated with significant reduction of the ATP and ADP levels in the 120-min reperfused hearts as compared with vehicle (Table 2) . Ischemia-reperfusion would cause a loss of high-energy phosphates either in pitavastatin-or rosuvastatin-treated heart. Pretreatment with pitavastatin caused the additional reduction of ATP and ADP levels in the reperfused hearts, whereas that with rosuvastatin did not ( Table 2) . Lipophilic pitavastatin can penetrate the cell membrane, enter the myocardial cell, and aggravate the ATP generating system in mitochondria through inhibition of ubiquinone biosynthesis. On the other hand, hydrophilic rosuvastatin as well as pravastatin cannot enter the myocardial cell and thus did not affect the ATP generating system. We speculate that aggravation of myocardial stunning may be related to the hydrophilic / lipophilic properties of the statins.
Usually oxygen deficiency accelerates glycolysis inducing anaerobic production of ATP. The levels of glucose-6-phosphate, fructose-6-phosphate, and lactate, which are glycolytic intermediates, are increased by ischemia and returned to pre-ischemic levels by reperfusion (3, 10) . There were no significant differences between groups in the levels of glycolytic intermediates (Table 2 ). This result suggests that the oxygen supplydemand balance was not disturbed even when pitavastatin worsened the myocardial stunning. Another mechanism may be involved in worsening of the myocardial stunning with lipophilic statins. Isoprenoids generated from mevalonic acid are required for isoprenylation of several proteins in signal transduction, including small molecular weight guanosine triphosphate (GTP)-binding proteins and the γ-subunits of heterotrimetric GTP-binding proteins (5) . When the myocardial contraction decreases under some pathophysiological conditions, such as ischemia, catecholamines are released and restore the myocardial contraction (16) . If lipophilic statins enter the myocardial cell and prevent isoprenylation of these proteins, some responses of myocardial cells to catecholamines may be attenuated.
Two major mechanisms are advocated to explain the pathophysiology of myocardial stunning (17) . One is the generation of oxygen-derived free radicals and another is a transient calcium overload. In fact, probucol and fluvastatin show the antioxidative effects on lipid peroxidation in vitro (18, 19) . However, it is not clear at present whether deterioration of myocardial stunning with pitavastatin is related to these mechanisms.
Because the plasma concentrations of the statins were not measured in the present study, we calculated those based on the body surface area. The body surface area of a dog (10 kg body weight and 80 cm height) is 0.46 m 2 , and that of a human (60 kg body weight and 170 cm height) is 1.7 m 2 . Rosuvastatin at the clinical dose of 2.5 -20 mg / 60 kg can be converted to 1.5 -11.8 mg / m 2 of the body surface area of a human. Pitavastatin at the clinical dose of 1 -4 mg/ 60 kg can also be converted to 0.6 -2.4 mg / m 2 . In the present study, dogs were given 2 mg/ kg rosuvastatin and 0.4 mg / kg pitavastatin. The calculated doses based on the body surface area of the dog were 43.5 mg / m 2 for rosuvastatin and 8.7 mg / m 2 for pitavastatin. Therefore, the dose of rosuvastatin used here was 3.7-to 29-fold of its clinical dose, and that of pitavastatin 3.6-to 14.5-fold. The doses of statins given to the dogs in the present study were high as compared with the clinical doses. However, some pathological conditions may increase the concentration of statin in blood more than 10-fold in patients (20, 21) . Although the animals in the present study took statins only for 3 weeks, patients with hypercholesterolemia take them for years. Clinical prevention studies with statins have been reported (22 -28) . In all reports, statins lowered the high blood cholesterol level and prevent coronary atherosclerosis. However, in some early reports, lipophilic statins did not show a significant reduction of the cardiac event rate (23 -25, 29) . We have proposed that the beneficial effect of lipophilic statins on coronary artery disease due to regression of atherosclerosis may be attenuated by the deleterious effect of the inhibitors on myocardial contractile function, especially under pathological conditions (1).
In conclusion, we confirmed that hydrophilic rosuvastatin, like pravastatin, did not show a significant influence on the myocardial stunning phenomenon in dogs. On the other hand, lipophilic pitavastatin deteriorated the stunning phenomenon. However, all patients taking either hydrophilic or lipophilic statins should be carefully controlled, because even hydrophilic statins can cause adverse events, such as hepatotoxicity associated with elevation in hepatic transaminase, myopathy, and rhabdomyolysis. Of course, pregnant women and nursing mothers should avoid taking statins.
